Legal & General Group PLC Aldeyra Therapeutics, Inc. Transaction History

Legal & General Group PLC

$470 Billion
Q3 2024

A detailed history of Legal & General Group PLC transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 4,397 shares of ALDX stock, worth $21,721. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,397

Previous 4,397 -0.0%

Holding current value

$21,721

Previous $23,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.19 - $6.32 $893 - $1,769	280 Added 6.8%	4,397 $23,000
Q2 2024 Aug 14, 2024	SELL	$3.25 - $4.72 $3,282 - $4,767	-1,010 Reduced 19.7%	4,117 $13,000
Q1 2024 May 14, 2024	SELL	$2.77 - $4.22 $11,670 - $17,778	-4,213 Reduced 45.11%	5,127 $16,000
Q4 2023 Feb 15, 2024	SELL	$1.47 - $6.06 $41,533 - $171,219	-28,254 Reduced 75.16%	9,340 $32,000
Q3 2023 Nov 14, 2023	SELL	$6.11 - $8.16 $1,851 - $2,472	-303 Reduced 0.8%	37,594 $251,000
Q2 2023 Aug 14, 2023	BUY	$7.11 - $11.89 $269,447 - $450,595	37,897 New	37,897 $317,000
Q2 2022 Aug 22, 2022	SELL	$2.43 - $4.85 $12,852 - $25,651	-5,289 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.25 - $5.17 $997 - $1,587	307 Added 6.16%	5,289 $24,000
Q4 2021 Feb 14, 2022	SELL	$3.5 - $9.63 $525 - $1,444	-150 Reduced 2.92%	4,982 $20,000
Q2 2021 Aug 12, 2021	BUY	$10.44 - $14.85 $53,578 - $76,210	5,132 New	5,132 $58,000
Q2 2020 Aug 14, 2020	SELL	$1.97 - $5.05 $7,690 - $19,715	-3,904 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$4.73 - $7.98 $2,942 - $4,963	622 Added 18.95%	3,904 $23,000
Q4 2018 Feb 15, 2019	BUY	$7.26 - $13.29 $6,693 - $12,253	922 Added 39.07%	3,282 $27,000
Q2 2018 Aug 10, 2018	BUY	$6.95 - $9.18 $16,402 - $21,664	2,360 New	2,360 $19,000

Others Institutions Holding ALDX

# of Institutions

117

Shares Held

36.4M

Call Options Held

196K

Put Options Held

142K

View Full List

About Aldeyra Therapeutics, Inc.

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $288M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

More about ALDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Aldeyra Therapeutics, Inc. Transaction History